XTAC Trademark

Trademark Overview

On Friday, February 11, 2022, a trademark application was filed for XTAC with the United States Patent and Trademark Office. The USPTO has given the XTAC trademark a serial number of 97263308. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Wednesday, May 15, 2024. This trademark is owned by Avilar Therapeutics, Inc.. The XTAC trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development in the field of pharmaceuticals targeting diseases mediated by extracellular proteins

General Information

Serial Number97263308
Word MarkXTAC
Filing DateFriday, February 11, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateWednesday, May 15, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 11, 2023

Trademark Statements

Goods and ServicesResearch and development in the field of pharmaceuticals targeting diseases mediated by extracellular proteins

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, February 16, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAvilar Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451
Party NameAvilar Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451

Trademark Events

Event DateEvent Description
Tuesday, February 15, 2022NEW APPLICATION ENTERED
Wednesday, February 16, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, September 3, 2022ASSIGNED TO EXAMINER
Tuesday, September 6, 2022NON-FINAL ACTION WRITTEN
Tuesday, September 6, 2022NON-FINAL ACTION E-MAILED
Tuesday, September 6, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, March 3, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, March 3, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 3, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, March 8, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 22, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 11, 2023PUBLISHED FOR OPPOSITION
Tuesday, April 11, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 6, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, December 4, 2023SOU TEAS EXTENSION RECEIVED
Monday, December 4, 2023SOU EXTENSION 1 FILED
Monday, December 4, 2023SOU EXTENSION 1 GRANTED
Wednesday, December 6, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 6, 2024SOU EXTENSION 2 FILED
Monday, May 6, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, May 15, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, May 15, 2024SOU EXTENSION 2 GRANTED
Thursday, May 16, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 5, 2024SOU TEAS EXTENSION RECEIVED

Related Keywords

xtac mediated extracellular proteins diseases targeting development field pharmaceuticals research